Lipapa, Zyrex .
HRN: 25-40-54 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/19/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
11/19/2024
11/25/2024
IV
60
Q24Hrs
PCAP
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes